Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts by Nicholas J. Short, Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica Leonard, Aaron C. Logan, Jae Park, Bijal Shah, Wendy Stock, Elias Jabbour

Get full text

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab by Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar, Sanam Loghavi, Lewis Nasr, Fadi G. Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi, Elias Jabbour

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase... by Mahesh Swaminathan, Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Navel G. Daver, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Nicholas J. Short, William G. Wierda, Nitin Jain, Steven M. Kornblau, Lucia Masarova, Sherry A. Pierce, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Y. Konopleva

Get full text